From: Cost-effectiveness analysis of the prevention of mother-to-child transmission of HIV
Items | Value |
---|---|
Costs (USD in million) | Â |
 PMTCT (HIV test, ART, etc.) | 114.1 |
Effectiveness | Â |
 No. of pregnant women preliminary tested for HIV | 34,991 |
 No. of identified HIV + women | 663 |
 No. of HIV + women volunteering to terminate pregnancy | 28 |
 No. pediatric infections averted | 164 |
 Life years gained (person-years) | 630.6 |
 Direct benefits (USD in million) | 198.4 |
 Indirect benefits (USD in million) | 82.5 |
Cost-effectiveness | Â |
 Cost per pregnant women preliminary screening tested for HIV (USD) | 3.5 |
 Cost per pregnant women reinspected for HIV (USD) | 296.6 |
 Cost per pediatric infections averted (USD) | 6957.9 |
 Cost utility ratio | 1809.5 |
 Benefit–cost ratio | 1.5 |